



**THE AMGEN  
INTERNATIONAL PRIZE  
FOR THERAPEUTIC  
ADVANCEMENT  
IN NEPHROLOGY**



**The International Society of Nephrology (ISN)**

ANNOUNCES A



**CALL FOR NOMINATIONS**

The AMGEN International Prize for Therapeutic Advancement of Nephrology recognizes the increased understanding and treatment of kidney disease through basic or clinical scientific research leading to therapeutic advances. The inaugural prize in 2003 was made at the ISN 2003 World Congress in Berlin to Barry M. Brenner, MD of Brigham and Women's Hospital, and Harvard University, Boston, USA, for establishing the foundations of our understanding of the progression of chronic kidney disease and its retardation by blockade of the renin angiotensin system in experimental and clinical studies leading to major benefit to millions of patients with diabetes, hypertension and other kidney disease.

The recipient of the 2005 Prize will receive \$50,000 and a framed certificate with an appropriate citation. Normally, the prize is to be awarded to a single individual. If two individuals are selected, they will share the prize equally. The prize will be awarded without restrictions to nationality, race, religion, or gender. The Advisory Committee representing members of the ISN and AMGEN will recommend recipients of the Prize. Amgen acts in an advisory capacity but is not on the independent selection committee. To be considered for the Prize, nomination letters must be sent to the following address:

JOHN H. DIRKS, M.D.  
CHAIR, AMGEN PRIZE ADVISORY COMMITTEE  
MASSEY COLLEGE, 4 DEVONSHIRE PLACE  
TORONTO ON, CANADA, M5S 2E1

FAX: 416 946 3302; EMAIL: john.dirks@utoronto.ca



**DEADLINE FOR NOMINATIONS is September 13th, 2004**

Please note, self-nominations will not be considered by the committee

**A complete nomination package should include:**

1. A formal letter of nomination that contains:
  - (a) Statement declaring whether the award should be made to an individual or whether it should/could be shared with other scientists who may or may not be included in the nomination
  - (b) Summary of the contributions of the nominee(s)
  - (c) Description of how and why the work of the nominee(s) represents a major advance in our understanding & treatment of kidney disease through basic or clinical scientific research leading to therapeutic advances & distinguishing those aspects of the work of the nominee(s) that clearly sets it apart from the work of others in the field
2. A full curriculum vitae and list of publications for the nominee(s)
3. At least two letters of support for the nomination
4. The full name and complete contact information for both the nominees and the nominator(s).  
The Advisory Committee representing members of the ISN and AMGEN will review all nominations and make the final recommendation for the recipient(s) of the Prize.

**THE PRIZE WILL BE PRESENTED AT THE ISN CONGRESS IN SINGAPORE, JUNE 26-30, 2005**

This Prize is made possible by the generosity and vision of AMGEN in Thousand Oaks, California  
For Terms of Reference and further information consult the ISN Website: [www.isn-online.org](http://www.isn-online.org)